Cargando…

SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare, aggressive cancer. Up to 75% of patients develop incurable metastatic disease, highlighting an urgent need for novel medical therapies. We recently identified a rapidly progressive ACC subtype characterized by CpG island hypermethylation (CIMP-high), sustain...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Dipika R, Finco, Isabella, LaPensee, Christopher Ryan, Rege, Juilee, Else, Tobias, Almeida, Madson Q, Vinco, Michelle, Wakamatsu, Alda, Latronico, Ana Claudia, Mendonca, Berenice Bilharinho, Zerbini, Maria Claudia N, Fragoso, Maria Candida Barisson Villares, Rainey, William E, Venneti, Sriram, Marie, Suely K N, Giordano, Thomas J, Lerario, Antonio Marcondes, Hammer, Gary D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208394/
http://dx.doi.org/10.1210/jendso/bvaa046.2265
_version_ 1783530835010387968
author Mohan, Dipika R
Finco, Isabella
LaPensee, Christopher Ryan
Rege, Juilee
Else, Tobias
Almeida, Madson Q
Vinco, Michelle
Wakamatsu, Alda
Latronico, Ana Claudia
Mendonca, Berenice Bilharinho
Zerbini, Maria Claudia N
Fragoso, Maria Candida Barisson Villares
Rainey, William E
Venneti, Sriram
Marie, Suely K N
Giordano, Thomas J
Lerario, Antonio Marcondes
Hammer, Gary D
author_facet Mohan, Dipika R
Finco, Isabella
LaPensee, Christopher Ryan
Rege, Juilee
Else, Tobias
Almeida, Madson Q
Vinco, Michelle
Wakamatsu, Alda
Latronico, Ana Claudia
Mendonca, Berenice Bilharinho
Zerbini, Maria Claudia N
Fragoso, Maria Candida Barisson Villares
Rainey, William E
Venneti, Sriram
Marie, Suely K N
Giordano, Thomas J
Lerario, Antonio Marcondes
Hammer, Gary D
author_sort Mohan, Dipika R
collection PubMed
description Adrenocortical carcinoma (ACC) is a rare, aggressive cancer. Up to 75% of patients develop incurable metastatic disease, highlighting an urgent need for novel medical therapies. We recently identified a rapidly progressive ACC subtype characterized by CpG island hypermethylation (CIMP-high), sustained Wnt/β-catenin signaling, steroidogenic differentiation, and cell cycle activation. CIMP-high status alone accounts for 40% of ACC, but predicts 70% of recurrences and >50% of deaths. Intriguingly, hypermethylated CpG islands in CIMP-high ACC are unmethylated in fetal and adult adrenal cortex, suggesting DNA methylation is supported by cancer-specific mechanisms. We therefore sought to investigate how aberrant epigenetic programming contributes to ACC biology. In embryonic stem cells, the Polycomb repressive complex 2 (PRC2) represses differentiation programs through EZH2-mediated histone H3 lysine 27 trimethylation (H3K27me3) deposition in promoter CpG islands free of DNA methylation. Gain or loss of EZH2/PRC2 function prevails in a variety of human cancers, enabling proliferation in a tissue-specific manner. Here, we identify that CIMP-high ACC exhibit high expression of EZH2/H3K27me3, but paradoxically bear DNA hypermethylation in annotated PRC2 target regions. To determine if DNA methylation of PRC2 targets disrupts or is controlled by EZH2, we characterized EZH2’s role in CIMP-high ACC cell line NCI-H295R at baseline and in response to EZH2 inhibition (EZH2i). EZH2-directed IP-MS revealed EZH2 interacts with PRC2 members and DNA methylation-sensitive accessory proteins, but no DNA methyltransferase machinery. ChIP-seq revealed EZH2 and H3K27me3 colocalize in repressive domains genome-wide, but DNA methylation and H3K27me3 are mutually exclusive. EZH2i induced H3K27 demethylation and loss of viability, but with no effect on CIMP-high DNA methylation. These data suggest PRC2 target DNA methylation in CIMP-high ACC is maintained independently of EZH2, enabling EZH2/PRC2 to coordinate alternative programs required for cell survival. We then measured the consequences of EZH2i on the NCI-H295R transcriptome (RNA-seq), EZH2/H3K27me3 deposition genome-wide (ChIP-seq), and chromatin accessibility landscape (ATAC-seq). EZH2i led to global downregulation of cell cycle, Wnt/β-catenin transcriptional programming, and steroidogenic differentiation, partially explained by EZH2i-induced offloading of EZH2 from H3K27me3 domains to accessible promoters genome-wide. Taken together, our studies illustrate how aberrant CpG island hypermethylation in CIMP-high ACC participates in a targetable repressive epigenetic cascade that reinforces oncogenic adrenocortical transcriptional programs. Ultimately, we hope to illuminate novel strategies for tissue-specific disruption of the aberrant epigenetic wiring that defines CIMP-high ACC.
format Online
Article
Text
id pubmed-7208394
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72083942020-05-13 SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma Mohan, Dipika R Finco, Isabella LaPensee, Christopher Ryan Rege, Juilee Else, Tobias Almeida, Madson Q Vinco, Michelle Wakamatsu, Alda Latronico, Ana Claudia Mendonca, Berenice Bilharinho Zerbini, Maria Claudia N Fragoso, Maria Candida Barisson Villares Rainey, William E Venneti, Sriram Marie, Suely K N Giordano, Thomas J Lerario, Antonio Marcondes Hammer, Gary D J Endocr Soc Adrenal Adrenocortical carcinoma (ACC) is a rare, aggressive cancer. Up to 75% of patients develop incurable metastatic disease, highlighting an urgent need for novel medical therapies. We recently identified a rapidly progressive ACC subtype characterized by CpG island hypermethylation (CIMP-high), sustained Wnt/β-catenin signaling, steroidogenic differentiation, and cell cycle activation. CIMP-high status alone accounts for 40% of ACC, but predicts 70% of recurrences and >50% of deaths. Intriguingly, hypermethylated CpG islands in CIMP-high ACC are unmethylated in fetal and adult adrenal cortex, suggesting DNA methylation is supported by cancer-specific mechanisms. We therefore sought to investigate how aberrant epigenetic programming contributes to ACC biology. In embryonic stem cells, the Polycomb repressive complex 2 (PRC2) represses differentiation programs through EZH2-mediated histone H3 lysine 27 trimethylation (H3K27me3) deposition in promoter CpG islands free of DNA methylation. Gain or loss of EZH2/PRC2 function prevails in a variety of human cancers, enabling proliferation in a tissue-specific manner. Here, we identify that CIMP-high ACC exhibit high expression of EZH2/H3K27me3, but paradoxically bear DNA hypermethylation in annotated PRC2 target regions. To determine if DNA methylation of PRC2 targets disrupts or is controlled by EZH2, we characterized EZH2’s role in CIMP-high ACC cell line NCI-H295R at baseline and in response to EZH2 inhibition (EZH2i). EZH2-directed IP-MS revealed EZH2 interacts with PRC2 members and DNA methylation-sensitive accessory proteins, but no DNA methyltransferase machinery. ChIP-seq revealed EZH2 and H3K27me3 colocalize in repressive domains genome-wide, but DNA methylation and H3K27me3 are mutually exclusive. EZH2i induced H3K27 demethylation and loss of viability, but with no effect on CIMP-high DNA methylation. These data suggest PRC2 target DNA methylation in CIMP-high ACC is maintained independently of EZH2, enabling EZH2/PRC2 to coordinate alternative programs required for cell survival. We then measured the consequences of EZH2i on the NCI-H295R transcriptome (RNA-seq), EZH2/H3K27me3 deposition genome-wide (ChIP-seq), and chromatin accessibility landscape (ATAC-seq). EZH2i led to global downregulation of cell cycle, Wnt/β-catenin transcriptional programming, and steroidogenic differentiation, partially explained by EZH2i-induced offloading of EZH2 from H3K27me3 domains to accessible promoters genome-wide. Taken together, our studies illustrate how aberrant CpG island hypermethylation in CIMP-high ACC participates in a targetable repressive epigenetic cascade that reinforces oncogenic adrenocortical transcriptional programs. Ultimately, we hope to illuminate novel strategies for tissue-specific disruption of the aberrant epigenetic wiring that defines CIMP-high ACC. Oxford University Press 2020-05-08 /pmc/articles/PMC7208394/ http://dx.doi.org/10.1210/jendso/bvaa046.2265 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adrenal
Mohan, Dipika R
Finco, Isabella
LaPensee, Christopher Ryan
Rege, Juilee
Else, Tobias
Almeida, Madson Q
Vinco, Michelle
Wakamatsu, Alda
Latronico, Ana Claudia
Mendonca, Berenice Bilharinho
Zerbini, Maria Claudia N
Fragoso, Maria Candida Barisson Villares
Rainey, William E
Venneti, Sriram
Marie, Suely K N
Giordano, Thomas J
Lerario, Antonio Marcondes
Hammer, Gary D
SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
title SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
title_full SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
title_fullStr SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
title_full_unstemmed SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
title_short SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
title_sort sat-lb34 repressive epigenetic programs reinforce steroidogenic differentiation and wnt/β-catenin signaling in aggressive adrenocortical carcinoma
topic Adrenal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208394/
http://dx.doi.org/10.1210/jendso/bvaa046.2265
work_keys_str_mv AT mohandipikar satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT fincoisabella satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT lapenseechristopherryan satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT regejuilee satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT elsetobias satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT almeidamadsonq satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT vincomichelle satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT wakamatsualda satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT latronicoanaclaudia satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT mendoncaberenicebilharinho satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT zerbinimariaclaudian satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT fragosomariacandidabarissonvillares satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT raineywilliame satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT vennetisriram satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT mariesuelykn satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT giordanothomasj satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT lerarioantoniomarcondes satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma
AT hammergaryd satlb34repressiveepigeneticprogramsreinforcesteroidogenicdifferentiationandwntbcateninsignalinginaggressiveadrenocorticalcarcinoma